Department of Neuroradiology, Eberhard Karls University, Tübingen, Germany.
Institute of Neuropathology, Department of Pathology and Neuropathology, Eberhard Karls University, Tübingen, Germany.
Eur J Radiol. 2017 Oct;95:202-211. doi: 10.1016/j.ejrad.2017.08.008. Epub 2017 Aug 18.
To assess the diagnostic performance of histogram analysis of diffusion kurtosis imaging (DKI) maps for in vivo assessment of the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 CNS WHO) integrated glioma grades.
Seventy-seven patients with histopathologically-confirmed glioma who provided written informed consent were retrospectively assessed between 01/2014 and 03/2017 from a prospective trial approved by the local institutional review board. Ten histogram parameters of mean kurtosis (MK) and mean diffusivity (MD) metrics from DKI were independently assessed by two blinded physicians from a volume of interest around the entire solid tumor. One-way ANOVA was used to compare MK and MD histogram parameter values between 2016 CNS WHO-based tumor grades. Receiver operating characteristic analysis was performed on MK and MD histogram parameters for significant results.
The 25th, 50th, 75th, and 90th percentiles of MK and average MK showed significant differences between IDH1/2 gliomas, IDH1/2 gliomas, and oligodendrogliomas with chromosome 1p/19q loss of heterozygosity and IDH1/2 (p<0.001). The 50th, 75th, and 90th percentiles showed a slightly higher diagnostic performance (area under the curve (AUC) range; 0.868-0.991) than average MK (AUC range; 0.855-0.988) in classifying glioma according to the integrated approach of 2016 CNS WHO.
Histogram analysis of DKI can stratify gliomas according to the integrated approach of 2016 CNS WHO. The 50th (median), 75th and the 90th percentiles showed the highest diagnostic performance. However, the average MK is also robust and feasible in routine clinical practice.
评估扩散峰度成像(DKI)图直方图分析在活体评估 2016 年世界卫生组织中枢神经系统肿瘤分类(2016 年 CNS WHO)综合胶质瘤分级中的诊断性能。
回顾性评估了 2014 年 1 月至 2017 年 3 月期间,在获得当地机构审查委员会批准的前瞻性试验中,77 名经组织病理学证实的胶质瘤患者。由两名盲法医师从整个实体瘤的感兴趣容积中,独立评估 DKI 的平均峰度(MK)和平均弥散度(MD)指标的 10 个直方图参数。采用单因素方差分析比较 2016 年 CNS WHO 基于肿瘤分级的 MK 和 MD 直方图参数值。对 MK 和 MD 直方图参数进行了显著结果的受试者工作特征分析。
IDH1/2 胶质瘤、IDH1/2 胶质瘤和伴 1p/19q 染色体杂合性缺失的少突胶质细胞瘤之间,MK 和平均 MK 的 25%、50%、75%和 90%分位数存在显著差异(p<0.001)。在根据 2016 年 CNS WHO 综合方法对胶质瘤进行分类时,50%、75%和 90%分位数的诊断性能略高(曲线下面积(AUC)范围:0.868-0.991),而平均 MK(AUC 范围:0.855-0.988)。
DKI 图直方图分析可根据 2016 年 CNS WHO 的综合方法对胶质瘤进行分层。50%(中位数)、75%和 90%分位数显示出最高的诊断性能。然而,平均 MK 在常规临床实践中也是稳健且可行的。